Foghorn Therapeutics Inc.
NASDAQ:FHTXBiotechnology
+$0.10 today
- Market cap
- $107.33M
- Beta
- 2.89
- P/E (TTM)
- -3.8
- EPS (TTM)
- -$1.08
Volume 0.53M
Average 0.15M
FHTX Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Foghorn Therapeutics Inc.NASDAQ: FHTX
Operating Income · Q1 FY2026 · quarter ended Mar 2026
Operating income remains negative
Q1 FY2026 operating income was -$21.57M, compared with -$22.91M a year earlier. Trailing-twelve-month operating income was -$80.77M.
Context
- Operating income amounted to 265.6% of revenue in FY2025, down 188.7 pp from a year earlier.
- Operating income grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether operating income reaches the consensus estimate from 4 analysts of -$27M (+67.1%) for the fiscal year ending Dec 2026, a step up from the +20.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$21.57M-10.1% QoQ
- Last fiscal yearDec 2025
- -$82.11M+20.0% YoY
- LTMMar 2026
- -$80.77M+17.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +5.8% | +15.7% | +9.9 pp |
| 1 year | +20.0% | +67.1% | +47.1 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (82.11M) USD
- Year-over-year change
- +20.0%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (82.11M) | +20.0% |
| FY2024 | 2024-12-31 | (102.68M) | +4.8% |
| FY2023 | 2023-12-31 | (107.91M) | +7.9% |
| FY2022 | 2022-12-31 | (117.14M) | -16.3% |
| FY2021 | 2021-12-31 | (100.73M) | — |
Operating Income vs competitors
How FHTX compares with its peers on the latest reported figures
- FHTX's LTM Mar 2026 operating income of -$80.77M is the 5th highest of the 11 companies compared; the peer median is -$83.68M.
- Its year-over-year change of +17.1% is the 5th highest of 11, against a peer median of +2.6%.
- Operating income amounts to 286.2% of revenue for FHTX, versus a peer median of 196.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$13.55M | +69.6% | — | 19.1% | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | -$48.74M | +25.7% | — | — |
| LTM Mar 2026 | -$59.23M | +7.8% | — | — | |
| LTM Mar 2026 | -$60.38M | +40.9% | — | 87.2% | |
| LTM Mar 2026 | -$80.77M | +17.1% | — | 286.2% | |
ZURAZura Bio Limited | LTM Mar 2026 | -$81.49M | -23.4% | — | — |
| LTM Mar 2026 | -$85.87M | +19.6% | — | 619.6% | |
| LTM Mar 2026 | -$89.22M | -8.7% | — | 196.7% | |
| LTM Mar 2026 | -$113.89M | -2.6% | — | 5649.2% | |
| LTM Mar 2026 | -$160.36M | -111.1% | — | 73.6% | |
| LTM Mar 2026 | -$178.41M | -4443.0% | — | 3109.3% | |
| Peer median (excluding FHTX) | -$83.68M | +2.6% | — | 196.7% | |
Competitors are the stored peer set for FHTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.32M | 19.23M | 34.16M | 22.6M | 30.91M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 3.33M |
| Gross Profit | 1.32M | 19.23M | 34.16M | 22.6M | 27.58M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 89.2% |
| Research & Development | 80.33M | 105.62M | 109.69M | 94.53M | 85.47M |
| Selling, General & Admin | 21.73M | 30.75M | 32.37M | 28.36M | 27.55M |
| Operating Expenses | 102.05M | 136.37M | 142.06M | 125.29M | 109.68M |
| Depreciation & Amortization | 3.23M | 3.32M | 3.45M | 3.12M | 3.33M |
| EBITDA | (96.19M) | (105.56M) | (90.75M) | (97.17M) | (70.95M) |
| EBITDA Margin | -7292.4% | -549.0% | -265.7% | -429.9% | -229.5% |
| Operating Income | (100.73M) | (117.14M) | (107.91M) | (102.68M) | (82.11M) |
| Operating Margin | -7637.1% | -609.2% | -315.9% | -454.3% | -265.6% |
| Interest Income | 59K | 5.68M | 10.88M | 11.9M | 8.75M |
| Interest Expense | 1.91M | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (586K) | 8.26M | 13.71M | 16.06M | 7.82M |
| Income Before Tax | (101.32M) | (108.88M) | (94.2M) | (86.62M) | (74.28M) |
| Pre-Tax Margin | -7681.6% | -566.3% | -275.8% | -383.2% | -240.3% |
| Income Tax Expense | 0 | 0 | 4.23M | 0 | 0 |
| Net Income | (101.32M) | (108.88M) | (98.43M) | (86.62M) | (74.28M) |
| Net Margin | -7681.6% | -566.3% | -288.2% | -383.2% | -240.3% |
| EPS (Basic) | (2.78) | (2.62) | (2.34) | (1.58) | (1.18) |
| EPS (Diluted) | (2.78) | (2.62) | (2.34) | (1.58) | (1.18) |
| Weighted Avg Shares | 37.17M | 41.59M | 41.97M | 54.9M | 62.98M |
| Weighted Avg Shares (Diluted) | 37.17M | 41.59M | 41.97M | 54.9M | 62.98M |
Foghorn Therapeutics Inc.
NASDAQ:FHTX
Intrinsic Alpha fair value
Locked
Current Price
$1.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.